To test this, we administered SU5416, a VEGFR2 inhibitor, during the vascular remodeling period after stroke (Fig. 7a) and analyzed VEGFR2 activation and its downstream target Dll4 expression. The gene discussed is DLL4; the disease is stroke disorder.